Lytix To Take Lead Cancer Compound Into Clinic

Main Category: Cancer / Oncology
Article Date: 31 Mar 2008 - 3:00 PST

email to a friend   printer friendly   view / write opinions   rate article

The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead anti-cancer molecule LTX-315 through to clinical trials. This decision follows the selection of Lytix's first lead antimicrobial compound towards end of 2007.

According to Lytix Biopharma CEO Øystein Rekdal this is an important milestone for the company: "The identification of a highly effective and selective lead molecule within cancer further consolidates the broad drug potential of this novel class of synthetic peptides. We have teamed up with Bachem and Fulcrum to avoid delays in the drug development process."

About Lytix Biopharma AS

The Scandinavian based company Lytix Biopharma commercialises world-class research in synthetic peptide therapeutics by its founding scientists working in the University Hospital and University of Tromsø in Norway. The initial pipeline includes micro-size synthetic antimicrobial peptides (SAMPs™) for the treatment of multiresistant bacteria, fungal infections and cancer.

In addition to equity, the company and its research programme has received substantial grants from the Norwegian Research Council through its BIA and FUGE programmes. Lytix operates from state-of-the-art laboratories in the Tromsø Science Park with business development in Oslo. The development team has extensive experience of developing peptide based drugs, including preparation of peptides and peptidomimetics, synthesis of non-coded amino acids, medicinal chemistry, pharmacokinetics, QSAR and peptide drug design.

Lytix Biopharma AS